Evogene Ltd.
Tel Aviv Stock ExchangeTotal Valuation
Evogene Ltd. carries a market capitalization of 11.05M, placing it among publicly traded companies globally. Its enterprise value stands at 652.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.05M |
| Enterprise Value | 652.30M |
Share Statistics
Evogene Ltd. currently has 10.41M shares outstanding.
| Shares Outstanding | 10.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 432.31, and the price-to-book ratio stands at -2.27.
| PE Ratio | N/A |
| PS Ratio | 432.31 |
| PB Ratio | -2.27 |
| P/TBV Ratio | 81.70 |
| P/FCF Ratio | -78.59 |
| P/OCF Ratio | -78.46 |
Enterprise Valuation
| EV / Sales | 431.99 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Evogene Ltd. maintains a current ratio of 2.79, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.42, indicating elevated leverage, while an interest coverage ratio of 33.57 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.79 |
| Quick Ratio | 2.75 |
| Debt / Equity | 25.42 |
| Debt / EBITDA | -0.20 |
| Interest Coverage | 33.57 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -22.57 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.21 |
Taxes
| Income Tax | 2,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Evogene Ltd.'s stock has declined approximately -71.89829% over the past 52 weeks. The 50-day moving average sits at 185.44, while the 200-day moving average is 294.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | -71.89829% |
| 50-Day Moving Average | 185.44 |
| 200-Day Moving Average | 294.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Evogene Ltd. generated 1.51M in revenue and converted that into -5.90M in net income, yielding earnings per share of -1.41. EBITDA reached -10.17M, while operating income came in at -11.01M.
| Revenue | 1.51M |
| Gross Profit | -1.07M |
| Operating Income | -11.01M |
| Pretax Income | -11.59M |
| Net Income | -5.90M |
| EBITDA | -10.17M |
| EBIT | -11.01M |
| Earnings Per Share (EPS) | -1.41 |
Balance Sheet
Evogene Ltd. holds 13.05M in cash and equivalents against 2.03M in total debt, resulting in a net debt position of -8.51M. Total book value stands at -287.72M, with working capital of 9.60M providing operational flexibility.
| Cash & Cash Equivalents | 13.05M |
| Total Debt | 2.03M |
| Net Debt | -8.51M |
| Equity (Book Value) | -287.72M |
| Book Value Per Share | -35.00 |
| Working Capital | 9.60M |
Cash Flow
Evogene Ltd. produced -8.32M in operating cash flow over the past twelve months. After subtracting -14,000.00 in capital expenditures, free cash flow totaled -8.33M - equivalent to -1.01 per share.
| Operating Cash Flow | -8.32M |
| Capital Expenditures | -14,000.00 |
| Free Cash Flow | -8.33M |
| FCF Per Share | -1.01 |
Margins
Evogene Ltd. operates with a gross margin of -70.66, reflecting its pricing power and cost economics. The operating margin of -728.94 and net profit margin of -390.53 provide insight into operational efficiency.
| Gross Margin | -70.66 |
| Operating Margin | -728.94 |
| Pretax Margin | -767.81 |
| Profit Margin | -390.53 |
| EBITDA Margin | -673.71 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.99 |
| FCF Yield | -1.27 |
Stock Splits
Evogene Ltd.'s most recent stock split took place on November 19, 2013 with a 2:1 split ratio.
| Last Split Date | 11/19/2013 |
| Split Ratio | 2:1 |
Scores
Evogene Ltd. posts an Altman Z-Score of 15.54, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 15.54 |